The company
Business model
Board of directors
Intellectual property

Management Team

Mr. Marcus Bosson 


Marcus Bosson holds a MSc from Stockholm School of Economics, and has studied law at Stockholm University, Sweden. He worked at the Swedish-American Chamber of Commerce in New York City for four years, became later CEO of Ryda Bruk AB and has more than 20 years of experience from the venture capital industry as well as from the biotechnology/start-up industry. He is the founder of several successful companies to which he has raised approximately MUSD 100 in venture capital. Mr. Bosson co-founded QuiaPEG Pharmaceuticals AB in 2012.

Dr. Marek Kwiatkowski 


Marek Kwiatkowski holds a MSc from Jagiellonian University, Poland and a PhD from Uppsala University, Sweden. He has a long academic background within organic chemistry and has worked for large international companies as well as startup companies. He is co-founder of QuiaPEG Pharmaceuticals AB and the main inventor behind the company’s technology. In addition to his engagement in QuiaPEG, Dr. Kwiatkowski serves as Associated Professor at the Department of Bioorganic Chemistry at Uppsala University, Sweden.

Dr. Cecilia Kemi 

Cecilia Kemi holds an M.Sc. in Molecular Biology from Umeå University and a PhD in Lung Medicine and Allergology from Karolinska Institutet. For the past 15 years, Dr. Kemi has worked for both growing biotechnology companies and major global pharmaceutical companies, thereby gaining broad experience from a number of different therapy areas as well as organizational expertise in their various leadership roles. Dr. Kemi comes most recently from the global pharmaceutical company Novartis where she was the project manager for all of Novartis Nordics Pharma clinical Phase IV studies. She has co-authored more than ten scientific publications.

Dr. Vidar Wendel-Hansen 


Vidar Wendel-Hansen holds an MD and a PhD from Karolinska Institutet, Sweden. He has more than 20 years of industrial life science experience within a broad range of areas, such as molecular diagnostics, pre-clinical and clinical development and medical affairs. He has worked for large corporations such as Pharmacia Biotech, Gilead Sciences and Novartis as well as small biotech start-ups, and as Clinical Assessor at the Swedish Medical Products Agency. He is the author of 11 scientific papers and co-inventor of four patents. Dr Wendel-Hansen currently works in his own consulting company VWH & Company AB.

Dr. James M. Van Alstine 

James M. Van Alstine holds a BSc and a PhD from the University of British Columbia, Vancouver, Canada. He has an extensive academic background working with modification of proteins and surfaces with polymers such as pegylation. He has held the position as Professor both at the University of Alabama in Huntsville, USA and at the Royal Institute of Technology in Stockholm, Sweden before joining GE Healthcare. He is the author of approximately 100 scientific papers, and inventor or co-inventor on more than 50 patents. Prof. Van Alsteine currently works in his own consulting company JMVA Biotech AB.

Dr. Mats Reslow 

Mats Reslow holds a PhD from Lund University, Sweden. He has a long experience from life science industry, working with drug delivery and protein formulation, including pegylation, to increase peptide and protein half-life. He has worked in a variety of positions within companies such as Pharmacia, Ferring, Bioglan, SkyePharma and NovoNordisk. He is the author of 22 scientific papers and main inventor or co-inventor of 27 patents. Dr Reslow currently work as an independent consultant for several biotech companies in Sweden.
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message